RCKT Rocket Pharmaceuticals Inc

Price (delayed)

$2.91

Market cap

$317.75M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.87

Enterprise value

$291.08M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 10

Rocket Pharmaceuticals, Inc. is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company's platform-agnostic approach enables it ...

Highlights
Rocket Pharmaceuticals's EPS has increased by 29% YoY and by 7% from the previous quarter
RCKT's net income is up by 19% YoY and by 6% from the previous quarter
The equity has declined by 42% year-on-year and by 14% since the previous quarter
The quick ratio has declined by 34% year-on-year and by 5% since the previous quarter

Key stats

What are the main financial stats of RCKT

RCKT stock price

How has the Rocket Pharmaceuticals stock price performed over time
Intraday
-0.34%
1 week
-3.64%
1 month
-19.39%
1 year
-0.34%
YTD
-17.09%
QTD
-18.72%

Financial performance

How have Rocket Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$215.87M
Net income
-$209.38M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 20% YoY and by 7% from the previous quarter
RCKT's net income is up by 19% YoY and by 6% from the previous quarter

Price vs fundamentals

How does RCKT's price correlate with its fundamentals

Growth

What is Rocket Pharmaceuticals's growth rate over time

Valuation

What is Rocket Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.33
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Rocket Pharmaceuticals's EPS has increased by 29% YoY and by 7% from the previous quarter
The stock's price to book (P/B) is 58% less than its 5-year quarterly average of 3.2 but 11% more than its last 4 quarters average of 1.2
The equity has declined by 42% year-on-year and by 14% since the previous quarter

Efficiency

How efficient is Rocket Pharmaceuticals business performance
The ROIC has contracted by 13% from the previous quarter and by 12% YoY
RCKT's ROE is down by 9% YoY and by 8% from the previous quarter
The return on assets has declined by 6% since the previous quarter and by 6% year-on-year

Dividends

What is RCKT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RCKT.

Financial health

How did Rocket Pharmaceuticals financials performed over time
Rocket Pharmaceuticals's total assets has decreased by 39% YoY and by 14% from the previous quarter
The quick ratio has declined by 34% year-on-year and by 5% since the previous quarter
The debt is 90% smaller than the equity
Rocket Pharmaceuticals's debt to equity has soared by 67% YoY and by 11% from the previous quarter
The equity has declined by 42% year-on-year and by 14% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.